Venclose

What Venclose does

Venclose is a medical technology company that develops radiofrequency (RF) ablation solutions for the endovascular treatment of chronic venous disease (CVD) and venous insufficiency, including superficial vein reflux, incompetent perforator veins, and tributary vein reflux. Founded in 2014 and headquartered in San Jose, California, the company operates as a product brand within Becton, Dickinson and Company (NYSE: BDX), having been integrated into BD's Peripheral Intervention business unit.

The product platform consists of the Venclose RF Ablation System, anchored by the digiRF Generator and two specialized 6F single-use catheters: the Venclose RF Ablation Catheter, which features the only dual-heating length design (10 cm and 2.5 cm heating elements in a single catheter) for treating the great and small saphenous veins, and the Venclose Maven Perforator Catheter, which provides the only 360° circumferential heating coil RF solution for incompetent perforator and tributary veins. The system is positioned to ablate approximately 25% more vein length per heating cycle than the ClosureFast 8 cm catheter and to reduce total ablation time relative to quadrant ablation approaches. All devices are minimally invasive, single-use disposables that do not leave permanent implants.

Venclose generates revenue through hardware sales of disposable catheters and capital equipment (the digiRF Generator) to hospitals, outpatient clinics, and vein treatment centers, sold via enterprise field sales. Go-to-market leverages BD's established medical device sales force and the BD Advance Clinical Education and Training program to drive adoption among vascular surgeons, interventional radiologists, interventional cardiologists, and vein specialists across the United States. The company is privately held at the brand level, with no standalone revenue disclosure.

Name

Venclose

Legal name

Becton, Dickinson and Company

Website

https://venclose.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Venclose develops radiofrequency ablation catheters and generators for endovascular treatment of chronic venous disease, serving vascular surgeons, interventional radiologists, and vein specialists in U.S. healthcare facilities as a product brand within Becton, Dickinson and Company.

Ownership category

akta.pro rank

Product category

Venous Insufficiency Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Venous ablation devices
• Radiofrequency catheters
• Chronic venous disease
• Endovascular treatment
• Minimally invasive vascular

Headquarters

HQ city

San Jose

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Sale of RF ablation catheters (Venclose RF Ablation Catheter and Venclose Maven Perforator Catheter) and digiRF Generator to healthcare facilities. Single-use disposable catheters for procedural revenue, with generator as capital equipment or system component.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Venclose develops and sells a radiofrequency (RF) ablation system for endovascular treatment of chronic venous disease, including the Venclose RF Ablation Catheter with dual 10 cm and 2.5 cm heating lengths, the Venclose Maven 360° perforator catheter, and the digiRF Generator. The products are sold to healthcare facilities for treatment of superficial vein reflux, incompetent perforator veins, and tributary vein reflux in patients with venous insufficiency.

Product overview

Venclose is a medical device company offering a comprehensive RF ablation system for treating chronic venous disease (CVD). The product portfolio consists of the Venclose™ RF Ablation System as the core platform, which includes the digiRF™ Generator and two specialized catheters: the Venclose™ RF Ablation Catheter for superficial vein reflux (great saphenous vein and small saphenous vein treatment) featuring dual heating lengths (10 cm and 2.5 cm), and the Venclose Maven™ Perforator Catheter for treating incompetent perforator and tributary veins with 360° circumferential heating. All devices are 6F minimally invasive solutions using established RF technology that has been the predominant treatment approach for over 20 years.

Differentiator

Problem solved

Functional benefit

Brands

• Venclose RF Ablation System: Radiofrequency ablation system for treatment of superficial venous reflux disease, includes catheters and generator
• Venclose Maven Perforator Catheter
• digiRF Generator

Products and services

• Venclose RF Ablation System Comprehensive radiofrequency (RF) ablation treatment system for venous reflux disease, leveraging established RF technology (20+ years) as the predominant approach for chronic venous disease. Includes the digiRF Generator and compatible 6F minimally invasive catheters. Sold to hospitals, outpatient clinics, and vein treatment centers for use by vascular surgeons, interventional radiologists, interventional cardiologists, and phlebologists.
• Venclose RF Ablation Catheter (EVSRF Catheter) Single-use RF ablation catheter featuring the longest and only dual-heating length venous RF solution (10 cm and 2.5 cm heating elements) for treating superficial vein reflux in the great saphenous vein (GSV) and small saphenous vein (SSV). 6F low-profile flexible design with 1:1 torque ratio for navigating tortuous anatomy. Streamlines procedural efficiency by ablating 25% more vein length than the ClosureFast 8 cm Catheter and simplifies inventory management.
• Venclose Maven Perforator Catheter Single-use RF ablation catheter providing 360° circumferential resistive heating for incompetent perforator and tributary veins, with 20-second treatment cycles. 6F, 40 cm flexible design with 0.5 cm segmental ablation capability. Eliminates the need for repeated quadrant ablations by delivering uniform heating around the vessel circumference.
• digiRF Generator Capital RF generator that powers both Venclose catheters. Features compact design, simple catheter connection port, touch screen display with real-time procedure data, audible tones for thermal delivery, and catheter activation via handle or foot pedal. Sold to healthcare facilities as the system component for Venclose RF ablation procedures.

Quantifiable outcome

• Ablates 25% more vein length per heating cycle compared to ClosureFast 8 cm Catheter
• +3 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Penumbra: Penumbra's Indigo system for venous thrombosis and its expansion into peripheral vascular interventions place it as an emerging player competing for procedural share and capital budgets with venous specialists who also use Venclose.
• Inari Medical: Inari Medical focuses on venous thromboembolism interventions (ClotTriever, FlowTriever) and is expanding into chronic venous disease, making it an emerging competitor addressing adjacent procedural indications for the same vascular specialist customers.
• Merz Aesthetics: Merz markets Asclera (polidocanol) for sclerotherapy treatment of varicose veins, an alternative modality that competes for the same chronic venous disease treatment decisions, particularly in vein specialist outpatient practices.

Direct peers

• Medtronic: Medtronic's ClosureFast catheter is the dominant RF ablation system for chronic venous disease and is referenced throughout Venclose's own marketing as the primary performance benchmark — making it the most direct competitive peer.
• AngioDynamics: AngioDynamics offers endovenous RF ablation and laser ablation products (e.g., VenaCure EVLT) for treating superficial venous reflux, directly competing with the Venclose RF Ablation System in vascular surgeon and vein specialist accounts.
• Teleflex: Teleflex markets the VenaSeal cyanoacrylate closure system for venous reflux, a non-thermal modality that competes with Venclose's RF ablation approach for the same superficial vein reflux indication and customer base.
• Vascular Solutions (Teleflex): Vascular Solutions (now part of Teleflex) historically offered venous ablation and vascular access products targeting the same interventional radiology and vein specialist call points as Venclose.

Broad incumbents

• Boston Scientific: Boston Scientific operates broadly in peripheral vascular intervention through acquired platforms (including BTG's Varithena polidocanol microfoam for varicose veins), offering overlapping venous disease therapies and competing for the same hospital budgets as Venclose.
• BD (Becton, Dickinson and Company): BD is the parent company of Venclose and a broad incumbent in peripheral intervention; BD's broader peripheral vascular portfolio competes for the same hospital purchasing decisions and physician relationships that Venclose depends on.
• Philips: Philips operates broadly in image-guided therapy and peripheral vascular interventions; while not a direct venous RF ablation competitor, it competes for capital equipment budgets and integrated procedure-suite relationships at hospitals that purchase Venclose systems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Venclose